Evaluation of the Effectiveness of Photodynamic Therapy in the Treatment of Lesions of the Lichen Planus Type in the Oral Mucosa and Its Diagnostics With the Use of Autofluorescence, in Various Wavelength Ranges, in Combination With the Use of Texture Analysis and Fractal Dimension

Sponsor
Wroclaw Medical University (Other)
Overall Status
Completed
CT.gov ID
NCT04991012
Collaborator
(none)
30
1
2
16
1.9

Study Details

Study Description

Brief Summary

Lesions of the lichen planus type within the oral mucosa are now considered a potentially cancerous condition. One of the minimally invasive methods of treating these lesions is photodynamic therapy, and the gold standard in therapy is topical steroid administration

Condition or Disease Intervention/Treatment Phase
  • Device: PDT Therapy
  • Drug: Triamcinolone (Substance) therapy side
Phase 2

Detailed Description

Lichen planus shows an irregular shape, which is quite difficult to measure objectively, which is important in assessing the effectiveness of treatment.

Patients will be treated in protocol split mouth with the treatment of lesions on one cheek with a steroid (on an adhesive plaster) and on the other - photodynamic therapy with a foot sensitizer in the form of a methylene blue also on an adhesive plaster The treatment evaluation procedure will consist of taking a series of intraoral photographs. These photos will be taken at each visit. This procedure will involve taking pictures traditionally in "white" light and in the spectrum of 405 nm, 460 nm and 405 + 460 nm (using the unique feature of the prototype laser - emission of two wavelengths simultaneously) in order to induce autofluorescence of the mucosa and treated lesions to better visualize them

A prospective, randomized, single-blind 12-week clinical trial of full contralateral split-mouth in patients with bilateral erythematous or erosive lichen planus in the mouth.On one side, the OLP lesion eligible for treatment was subjected to photodynamic therapy using methylene blue in four sessions every 2 days.

olp on the other side was treated with the administration of the steroid triamcinolone for 8 days

The clinical evaluation of the evolution of OLP eruptions was performed within 12 weeks of qualifying for treatment: at baseline, at the end of both treatments (day 8) and after the next 11 weeks

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
full contralateral split-mouthfull contralateral split-mouth
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Evaluation of the Effectiveness of Photodynamic Therapy in the Treatment of Lesions of the Lichen Planus Type in the Oral Mucosa and Its Diagnostics With the Use of Autofluorescence, in Various Wavelength Ranges, in Combination With the Use of Texture Analysis and Fractal Dimension
Actual Study Start Date :
Feb 8, 2020
Actual Primary Completion Date :
Mar 8, 2021
Actual Study Completion Date :
Jun 10, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: photodynamic therapy side

On one side, the OLP lesion eligible for treatment was subjected to photodynamic therapy in four sessions every 2 days.Using as photosensitizer Methylen blue for 10min the lesion was irradiated with a 650 nm semiconductor laser at a dose of 120 J / cm2

Device: PDT Therapy
the olp was photosensitized with methylen blue and was irradiated with a semiconductor laser with a wavelength of 650 nm, using a dose of 120 J / cm2 and power density
Other Names:
  • Photodynamic Therapy
  • Active Comparator: Triamcinolone (Substance) therapy side

    on the other side The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days

    Drug: Triamcinolone (Substance) therapy side
    th The OLP on the other side was treated by daily sticking a cut-to-size carrier with 0.05% triamcinolone acetonide for 8 days
    Other Names:
  • Steroid therapy
  • Outcome Measures

    Primary Outcome Measures

    1. length of oral lichen planus [12 weeks]

      The measurement was made with a periodontal probe PCP UNC 15 in millimeters we measured the length of the lesions

    2. height of oral lichen planus [12 weeks]

      The measurement was made with a periodontal probe PCP UNC 15 in millimeters we measured the height

    Secondary Outcome Measures

    1. computer analysis of autofluorescence of lesions [12 weeks]

      Based on photos taken in various light spectrum and fractal analysis of changes In this study, we used two wavelengths: 405, 450 and 405+450 nm together for the autofluorescence of lesions All fractal analysis was performed in ImageJ version 1.53e (Image Processing and Analysis in Java) Applied the intensity difference fractal dimension counting method. We measured the size of oral lichen planus on photos taken with different light wave using computer program as mentioned above

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 85 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • histological diagnosis of OLP

    • non smoker

    • no diabetes melitus

    • no hepatitis

    Exclusion Criteria:
    • diabetes melitus

    • hepatitis

    • occurrence dysplasia in the histopathological specimen;

    • use of lichenoid reaction inducing medication and presence of amalgam fillings nearby the lesions;

    • interventions for OLP in the previous 12 weeks;

    • pregnant or breastfeeding women;

    • proved or suspected hypersensitivity to any of the chemicals used in the treatment

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Wroclaw Medical University Wrocław Dolnoslaskie Poland 50-425

    Sponsors and Collaborators

    • Wroclaw Medical University

    Investigators

    • Study Director: kamil jurczyszyn, prof, Wroclaw Medical University
    • Study Chair: tomasz konopka, prof, Wroclaw Medical University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Wroclaw Medical University
    ClinicalTrials.gov Identifier:
    NCT04991012
    Other Study ID Numbers:
    • kb845/2020
    First Posted:
    Aug 5, 2021
    Last Update Posted:
    Aug 5, 2021
    Last Verified:
    Jun 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Wroclaw Medical University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 5, 2021